Journal
JACC-CARDIOVASCULAR INTERVENTIONS
Volume 15, Issue 3, Pages 268-277Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jcin.2021.11.028
Keywords
acute coronary syndrome(s); dual antiplatelet therapy; network meta-analysis; percutaneous coronary intervention
Categories
Funding
- AstraZeneca
- Bayer
- Beth Israel Deaconess
- Bristol Myers Squibb/Sanofi
- CSL Behring
- Eli Lilly/Daiichi-Sankyo
- Medtronic
- Novartis
- OrbusNeich
- Amgen
- Biosensors
- CeloNova
- Daiichi-Sankyo
- Eisai
- Eli Lilly
- Gilead
- Idorsia
- Janssen
- Matsutani Chemical Industry
- Merck
- Osprey Medical
- Renal Guard Solutions
- Scott R. MacKenzie Foundation
Ask authors/readers for more resources
This study compares the effectiveness of short dual antiplatelet therapy (DAPT) and de-escalation in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). The results suggest that de-escalation reduces the risk of adverse cardiovascular events, while short DAPT decreases the occurrence of major bleeding.
OBJECTIVES The aim of this study was to compare short dual antiplatelet therapy (DAPT) and de-escalation in a network meta-analysis using standard DAPT as common comparator. BACKGROUND In patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), shortening DAPT and de-escalating to a lower potency regimen mitigate bleeding risk. These strategies have never been randomly compared. METHODS Randomized trials of DAPT modulation strategies in patients with ACS undergoing PCI were identified. All cause death was the primary outcome. Secondary outcomes included net adverse cardiovascular events (NACE), major adverse cardiovascular events, and their components. Frequentist and Bayesian network meta-analyses were conducted. Treatments were ranked on the basis of posterior probability. Sensitivity analyses were performed to explore sources of heterogeneity. RESULTS Twenty-nine studies encompassing 50,602 patients were included. The transitivity assumption was fulfilled. In the frequentist indirect comparison, the risk ratio (RR) for all-cause death was 0.98 (95% CI: 0.68-1.43). De-escalation reduced the risk for NACE (RR: 0.87; 95% CI: 0.70-0.94) and increased major bleeding (RR: 1.54; 95% CI: 1.07-2.21). These results were consistent in the Bayesian meta-analysis. De-escalation displayed a >95% probability to rank first for NACE, myocardial infarction, stroke, stent thrombosis, and minor bleeding, while short DAPT ranked first for major bleeding. These findings were consistent in node-split and multiple sensitivity analyses. CONCLUSIONS In patients with ACS undergoing PCI, there was no difference in all-cause death between short DAPT and de-escalation. De-escalation reduced the risk for NACE, while short DAPT decreased major bleeding. These data characterize 2 contemporary strategies to personalize DAPT on the basis of treatment objectives and risk profile. (J Am Coll Cardiol Intv 2022;15:268-277) (c) 2022 by the American College of Cardiology Foundation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available